Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Blosozumab Formulations in Postmenopausal Women
NCT02337387Phase 1Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2015
- Primary completion
- Mar 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of blosozumab in osteoporosis (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration. Started Jan 2015; status: terminated.
02
Drugs
blosozumab
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT02337387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02337387.